Vabysmo FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 31, 2022.
FDA Approved: Yes (First approved January 28, 2022)
Brand name: Vabysmo
Generic name: faricimab-svoa
Dosage form: Intravitreal Injection
Company: Genentech, Inc.
Treatment for: Macular Degeneration, Diabetic Macular Edema
Vabysmo (faricimab-svoa) is a bispecific antibody targeting the vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) pathways for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).
- Wet age-related macular degeneration is caused by growth of abnormal blood vessels into the macula. Diabetic macular edema occurs when damaged blood vessels in the retina leak into and cause swelling in the macula.
- Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) both contribute to vision loss by destabilizing blood vessels, causing inflammation and the formation of new leaky blood vessels in AMD and DME. Vabysmo works to stabilize blood vessels by blocking pathways involving Ang-2 and VEGF-A.
- Vabysmo is administered by intravitreal injection every 4 weeks for the first four doses, then at a regimen determined after clinical evaluation.
- Common adverse reactions include conjunctival hemorrhage.
Development timeline for Vabysmo
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.